Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report) has been assigned an average recommendation of “Buy” from the ...

GSK plc GSK announced positive headline data from the phase III GLISTEN study, which is evaluating its investigational ...

PBC patients receiving linerixibat saw statistically significant improvement in cholestatic pruritus - or relentless itch.

Drugmaker GSK said on Tuesday that its linerixibat candidate had shown "positive" Phase III results in cholestatic pruritus ...

UK pharma major GSK today announced positive headline results of GLISTEN, the ongoing global Phase III clinical trial ...

In December 2024, the Regulation on Deforestation-Free Products (EUDR) is anticipated to take effect, aiming to reduce ...

Interim results from the ongoing GLISTEN trial of linerixibat, GSK's targeted inhibitor of the ileal bile acid transporter ...

PBC treatments are available, even after the setback to Intercept Pharmaceuticals’ Ocaliva, but they are unable to reduce ...

GSK announces positive results from GLISTEN phase III trial of linerixibat in adults with cholestatic pruritus (relentless itch) associated with PBC: London, UK Wednesday, Novembe ...

GSK (GSK) announced headline results of GLISTEN, the ongoing global phase III clinical trial evaluating linerixibat, an investigational targeted inhibitor of the ileal bile acid transporter, IBAT, in ...

Trinity researchers have received awards for 6 projects out of a total 13 projects in the most recent call, and €5.3 million out of a €12.5 million investment from the Health Research Board (HRB) Five ...